In this new article by BioPharmaBoardroom, Dr. Andrew Lewis the Chief Scientific Officer at Quotient Sciences discusses the integration of AI into drug development.
AI in Drug Development: Balancing Innovation with Scientific Oversight
Drawing on its experience advancing an AI-designed drug product into clinical development, Quotient Sciences has seen how AI can accelerate formulation design, reduce drug substance requirements, and improve understanding of critical quality attributes.
Read the full article on BioPharmaBoardroom's website here.